Investors & Media

Press releases

Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

Visit our newsroom

Upcoming & recent events

Regeneron Roundtable: gMG & C5 Complement Program

Listen to webcast

View event details

Regeneron Pharmaceuticals Q1 2026 Earnings Conference Call

Listen to webcast

View event details

2026 Annual Meeting of Shareholders

Listen to webcast

View event details

View investor events

Quarterly materials

Show all

Q4 2025

Market Cap:

Mar 31, 2026 2:09 PM EDT

Minimum 15 minutes delayed. Source: LSEG

Interactive analyst center

Interactive and downloadable financial data for investors and analysts.

View analyst center

Corporate responsibility

We're dedicated to responsible business practices, integrating the highest standards of integrity into every facet of our operations.

Learn about our approach to corporate responsibility

Contact us

Investors

914.847.7741

invest@regeneron.com

Media

media@regeneron.com

Sign up for email alerts

Regeneron corporate and R&D headquarters